Clinical, Hematological Profile and Status of Iron Overload in Children with Transfusion Dependent Thalassemia : A Study from Rural Northern India
Asian Hematology Research Journal,
Thalassemias are one of most common type of haemolytic anaemia caused due to ineffective erythropoiesis requiring lifelong blood transfusions leading to chronic iron overload resulting in vasrious complications restricting the life span of most patients to 3rd-4th decade.
Objective: To evaluate clinical, haematological profile and status of iron overload in patients of transfusion dependent thalassemia.
Methods: We have enrolled 42 patients presenting to our centre for regular blood transfusion, the participants were followed up for a period of 1 year and samples were send at 3 monthly interval for CBC, Serum ferritin(S.F) , Serum Iron(S.I) and TIBC.
Results: The most frequent presenting complaints was pallor, incidence of malnourishment was 45.2%,the mean haemoglobin at time of presentation was 6.8± 2.9 g/dl, the mean S.F(ng/ml) and S.I(mcg/dl) at commencement of study was 2059.45 ± 2082.92 and 248.99 ± 92.95 while these values increased to 2610.57 ± 2245.64 and 349.05 ± 110 respectively after 1 year follow-up. All patients received chelation therapy either in form of Deferasirox (mean S.F=1639 ± 962 mean S.I=274.5 ± 76.7) or a combination of Deferasirox and Deferiprone (mean S.F= 5350 ± 3349.7 mean S.I=397.9 ± 128.2).
Conclusion: Majority of participants are inadequately transfused and chelation therapy was not effective in preventing iron overload which mandates a need of better and more effective chelators, revision of transfusion guidelines as well as proper counselling regarding attitude and behaviour of caregivers.
- blood transfusion
- iron overload
- chelation therapy
How to Cite
Gao C, Li L, Chen B, Song H, Cheng J, Zhang X, Sun Y. Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient preference and adherence. 2014; 8:513.
Marwaha RK, Lal A: Present status of hemoglobinopathies inIndia: Indian Pediatrics, 1994;3:267-71.
Kolnagou A, Kontoghiorghes GJ. Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Front Biosci (Landmark Ed). 2018;23:1082-1098.
Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, Goudarzi M, Pourkarim H, Azad M. A review on iron chelators in treatment of iron overload syndromes. International Journal of Hematology-Oncology and Stem Cell Research. 2016;10(4):239.
Simhachalam M, Sahoo M, Kuppili U. A study on growth profiles in children with thalassemia major between 2-10 years of age on regular transfusions and oral chelation therapy. Int J Pediatr Res. 2018; 5(2):78-86.
George A, Bhaduri A ,Sen S ,Choudhry VP. Physical growth parameters in thalassemic children. Indian J Pediatr. 1997;64:861–871
Pemde HK, Chandra J, Gupta D, Singh V, Sharma R, Dutta AK. Physical growth in children with transfusion-dependent thalassemia. Pediatric Health, Medicine and Therapeutics. 2011;2:13-9.
Biswas B, Naskar NN, Basu K, Dasgupta A, Basu R, Paul B. Malnutrition, its attributes, and impact on quality of life: an epidemiological study among β-thalassemia Major Children. Korean journal of family medicine. 2021;42(1):66.
Fuchs GJ, Tienboon P, Linpisarn S, Nimsakul S, Leelapat P, Tovanabutra S, Tubtong V, DeWier M, Suskind RM. Nutritional factors and thalassaemia major. Archives of disease in childhood. 1996; 74(3):224-7.
Phadke SR, Agarwal S. Phenotype score to grade the severity of thalassemia intermedia. The Indian Journal of Pediatrics. 2003;70(6):477-81.
Shah R, Trehan A, Das R, Marwaha RK. Serum ferritin in thalassemia intermedia. Indian Journal of Hematology and Blood Transfusion. 2014;30(4):281-5.
Kumar S, Singh D, Garg A. An epidemiological study on the clinico-hematological profile of pediatric patients with congenital hemolytic anemia. Int. J. Contemp. Pediat. 2017;4:374-7.
Ali MR, Bari MI, Mia MS, Rahman MK, Hossain MF, Sharmin LS. Clinical Profile of Thalassemia Syndrome in Children of Northern Bangladesh. TAJ: Journal of Teachers Association. 2018;31(2):6-11.
Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Annals of hematology. 2012;91(7):1107-14.
Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. European journal of haematology. 2005;74(2):93-100.
Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian journal of ophthalmology. 2010;58(2):125.
Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK. Safety and efficacy of deferasirox in multitransfused Indian children with β‐thalassaemia major. Ann Trop Paediatr 2011;31:47‐51
Abstract View: 101 times
PDF Download: 18 times